Continuation of systemic treatment in patients with cutaneous T-cell lymphoma is associated with reduced health care resource utilization
Background: Treatment for cutaneous T-cell lymphoma (CTCL) consists of skin-directed therapies for early-stage and systemic therapies (ST) for advanced disease. STs include extracorporeal photopheresis (ECP), retinoids, interferons, histone deacetylase inhibitors (HDACi), human antibodies, and chemotherapy, according to the NCCN guidelines. We conducted a database analysis to assess ST continuation.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
More News: Academies | Chemotherapy | Cutaneous T cell lymphoma | Databases & Libraries | Dermatology | Health Management | Lymphoma | Skin | T-cell Lymphoma